- Home
- FRBA vs MAZE Comparison
FRBA vs MAZE Comparison
Compare FRBA & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRBA
- MAZE
- Stock Information
- Founded
- FRBA 2007
- MAZE 2018
- Country
- FRBA United States
- MAZE United States
- Employees
- FRBA N/A
- MAZE N/A
- Industry
- FRBA Major Banks
- MAZE
- Sector
- FRBA Finance
- MAZE
- Exchange
- FRBA Nasdaq
- MAZE NYSE
- Market Cap
- FRBA 363.6M
- MAZE 367.0M
- IPO Year
- FRBA N/A
- MAZE 2025
- Fundamental
- Price
- FRBA $15.82
- MAZE $15.24
- Analyst Decision
- FRBA Buy
- MAZE Strong Buy
- Analyst Count
- FRBA 1
- MAZE 4
- Target Price
- FRBA $17.00
- MAZE $23.50
- AVG Volume (30 Days)
- FRBA 51.9K
- MAZE 125.7K
- Earning Date
- FRBA 07-22-2025
- MAZE 08-14-2025
- Dividend Yield
- FRBA 1.51%
- MAZE N/A
- EPS Growth
- FRBA 36.40
- MAZE N/A
- EPS
- FRBA 1.54
- MAZE 0.34
- Revenue
- FRBA $128,215,000.00
- MAZE $167,500,000.00
- Revenue This Year
- FRBA $5.46
- MAZE N/A
- Revenue Next Year
- FRBA $6.18
- MAZE N/A
- P/E Ratio
- FRBA $10.32
- MAZE $44.89
- Revenue Growth
- FRBA 20.76
- MAZE N/A
- 52 Week Low
- FRBA $12.69
- MAZE $6.71
- 52 Week High
- FRBA $16.47
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- FRBA 57.81
- MAZE N/A
- Support Level
- FRBA $15.88
- MAZE N/A
- Resistance Level
- FRBA $16.27
- MAZE N/A
- Average True Range (ATR)
- FRBA 0.33
- MAZE 0.00
- MACD
- FRBA 0.04
- MAZE 0.00
- Stochastic Oscillator
- FRBA 67.50
- MAZE 0.00
About FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.